Abstract
In summary, precise PTH measurements have been difficult and complex as a result of low circulating concentrations of biologically active hormone and the immunoheterogeneity of circulating PTH molecules. The differences in secretion rates and metabolism of various PTH fragments in different clinical disorders further complicated the interpretation of various radioimmunoassable PTH levels. In recent years, the development of two-site or intact immunometric assays represents significant advancements in PTH measurement. These assays, for the first time, provide the long-awaited sensitivity and precision of PTH measurement. The IRMA assay has certainly overcome the difficulties in accurately diagnosing parathyroid disorders and the difficulties in the differential diagnosis of hypercalcemia. Above all, these assays are more convenient and more specific in patients with compromised renal function.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
